Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 2/20 | 0.37 |
| ▸ | CA2 | P00918 | 2/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
| ▸ | BLM | P54132 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31744389 | 1.00 | MEN1 (0.38) | MEN1KMT2ACA1CA2CA9 | |
| SCHEMBL21165446 | 0.91 | MEN1 (0.34) | MEN1KMT2ACA1CA2CA9 | |
| SCHEMBL21165440 | 0.87 | MEN1 (0.32) | MEN1KMT2ACA1CA2ACHE | |
| SCHEMBL21165442 | 0.87 | MEN1 (0.32) | MEN1KMT2ACA1CA2ACHE | |
| SCHEMBL21165428 | 0.86 | CYP1A2 (0.41) | MEN1KMT2ACA1CA2CA9 | |
| SCHEMBL21165269 | 0.86 | CYP1A2 (0.41) | MEN1KMT2ACA1CA2CA9 | |
| SCHEMBL20604217 | 0.85 | CA1 (0.36) | MEN1KMT2ACA1CA2CA9 | |
| SCHEMBL21165360 | 0.85 | MEN1 (0.40) | MEN1KMT2ACA1CA2CA9 | |
| SCHEMBL20604216 | 0.85 | CA1 (0.36) | MEN1KMT2ACA1CA2CA9 | |
| SCHEMBL21165358 | 0.84 | CA1 (0.42) | MEN1KMT2ACA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3423433-B1 | SULFAMATE DERIVATIVE COMPOUNDS, PROCESSES FOR PREPARING THEM AND THEIR USES | BIO PHARM SOLUTIONS CO LTD (KR) | 2025-12-17 | — | — | EP | claimed |
| EP-3423433-B1 | SULFAMATE DERIVATIVE COMPOUNDS, PROCESSES FOR PREPARING THEM AND THEIR USES | BIO PHARM SOLUTIONS CO LTD (KR) | 2025-12-17 | — | — | EP | disclosed |
| US-10351519-B2 | Sulfamate derivative compounds, processes for preparing them and their uses | BIO-PHARM SOLUTIONS CO., LTD. (KR) | 2019-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10351519-B2 | Sulfamate derivative compounds, processes for preparing them and their uses | STS, SULT2A1, SULT1A1 | MEN1 2074/4885KMT2A 769/4885CA1 300/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.